Sources: Genzyme proposes contingent-value deal for sale of shares

11/22/2010 | Wall Street Journal, The

Genzyme, which continues to reject a $69-per-share bid by Sanofi-Aventis, is considering using a contingent-value right, a deal structure that might end the takeover deadlock, sources said. The structure gives shareholders a financial benefit if the acquired company reaches certain milestones. Genzyme reportedly is also integrating the structure in talks with other potential buyers.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY